CD274 and autoimmune disease: Drugs targeting the PD-1/PD-L1 axis can not only trigger potential autoimmune responses by enhancing T cell-mediated mechanisms but also induce autoantibody production via B cell-mediated mechanisms, thus further enhancing humoral immune responses, disrupting self-tolerance, and ultimately causing autoimmune diseases by attacking autoantigens24.